Carnitine palmitoyltransferase
From Proteopedia
(Difference between revisions)
| Line 19: | Line 19: | ||
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| + | [[2le3]] – hCPT I regulatory domain – human - NMR<br /> | ||
| + | [[2m76]] - hCPT I regulatory domain – NMR<br /> | ||
[[2h4t]], [[2fyo]], [[2deb]] – rCPT II – rat<br /> | [[2h4t]], [[2fyo]], [[2deb]] – rCPT II – rat<br /> | ||
[[2fw3]] - rCPT II + antidiabetic drug<br /> | [[2fw3]] - rCPT II + antidiabetic drug<br /> | ||
[[2rcu]] – rCPT II + substrate analog<br /> | [[2rcu]] – rCPT II + substrate analog<br /> | ||
[[4ep9]], [[4eph]], [[4eyw]] - rCPT II + inhibitor<br /> | [[4ep9]], [[4eph]], [[4eyw]] - rCPT II + inhibitor<br /> | ||
| - | [[2le3]] – hCPT I regulatory domain – human - NMR<br /> | ||
| - | [[2m76]] - hCPT I regulatory domain – NMR<br /> | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 07:09, 1 July 2020
| |||||||||||
3D structures of carnitine palmitoyltransferase
Updated on 01-July-2020
2le3 – hCPT I regulatory domain – human - NMR
2m76 - hCPT I regulatory domain – NMR
2h4t, 2fyo, 2deb – rCPT II – rat
2fw3 - rCPT II + antidiabetic drug
2rcu – rCPT II + substrate analog
4ep9, 4eph, 4eyw - rCPT II + inhibitor
References
- ↑ Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004 Oct-Dec;25(5-6):495-520. PMID:15363638 doi:http://dx.doi.org/10.1016/j.mam.2004.06.004
- ↑ Rufer AC, Lomize A, Benz J, Chomienne O, Thoma R, Hennig M. Carnitine palmitoyltransferase 2: analysis of membrane association and complex structure with a substrate analog. FEBS Lett. 2007 Jul 10;581(17):3247-52. Epub 2007 Jun 8. PMID:17585909 doi:10.1016/j.febslet.2007.05.080
